Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1646-1651

  Harvey, Harold A ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Hormonal therapy; Lytic bone lesions; Metastatic breast carcinoma; Parathyroid hormone related protein; Skeletal related events

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FADROZOLE; FLUOROURACIL; FLUOXYMESTERONE; FOLINIC ACID; FORMESTANE; HYDROCORTISONE; LETROZOLE; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; PARATHYROID HORMONE RELATED PROTEIN; TAMOXIFEN; VINBLASTINE;

BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0030847833     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1646::aid-cncr14>3.0.co;2-%23     Document Type: Conference Paper

References (36)

1. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormonerelated protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
2. Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer Treat Rev 1985;12:251-7.
3. Scheid V, Buzdar AU, Smith TL, Hortobagyi GN. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 1986;58: 2589-93.
4. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, et al. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 1994;35:1748-52.
5. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol 1991;18:11-5.
6. Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995;13:1123-8.
7. Ogata H, Fukutomi T. Problems in assessing the response to therapy on bone metastases in breast cancer: analysis of postrecurrence prognostic factors. Keio J Med 1993;42:14-7.
8. Nomura Y, Tominaga T, Adachi I, Koyama H, Fukami A. Clinical evaluation of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) on advanced and recurrent breast cancer. Clinical study group of CMF for breast cancer in Japan. Jpn J Cancer Chemother 1994;21(12):1949-56.
9. Ravdin PM, Burns HA III, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenendione-resistant breast cancer. J Clin Oncol 1995;13:2879-85.
10. Abrams JS, Vena DA, Baltz J, et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J Clin Oncol 1995;13:2056-65.
11. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Homer D, et al. Vinorelbine (navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 1994;5(5):423-6.
12. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-91.
13. Izumi M, Iino Y, Yokoe T, Inoue T, Yamada T, Kobayashi I, et al. Advanced breast cancer with remarkable response to the combination therapy of mitoxantrone (MIT) and medroxyprogesterone acetate (MPA) after failure of anthracycline therapy: a case report. Jpn J Cancer Chemother 1994;21: 265-8.
14. Hainsworth JD. The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancer. Ann Oncol 1993;4(Suppl 2):37-40.
15. Alberto P. Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. Ann Oncol 1993;4(5): 423-5.
16. Louvet C, de Gramont A, Demuynck B, Beerblock K, Varette C, Soubrane D, et al. Folinic acid, 5-fluorouracil bolus and infusion and mitoxantrone with or without cyclophosphamide in metastatic breast cancer. Eur J Cancer 1993;29A: 1835-8.
17. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995;13:2483-9.
18. Guise TA, Yoneda T, Yates AJ, Mundy GR. The combined effect of tumor-producing parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol 1993;77:40-5.
19. Brule G. Co-operative clinical study of 178 patients treated with "Nolvadex." In: The hormonal control of breast cancer. Ardsley Park, Macclesfeld, Cheshire, UK: ICI Ltd Pharmaceuticals Division, 1978:35-9.
20. Lerner HJ, Band PR, Israel L, Leung BS. Phase II study of tamoxifen: report of 74 patients with Stage IV breast cancer. Cancer Treat Rep 1976;60:1431-5.
21. Rubens RD, Tinson CL, Coleman RE, et al. Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer 1988;55:626-30.
22. Blackledge GRP, Latief T, Mould JJ, Spooner D, Morrison M. Phase II evaluation of megestrol acetate in previously treated patients with advanced breast cancer relationship of response of previous treatment. Eur J Cancer Clin Oncol 1986;22:1091-4.
23. Hortobagyi GN, Buzdar AU, Frye D, et al. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat 1985;5:321-6.
24. Kaye SB, Woods RL, Fox RM, Coates AS, Tattersall MHN. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer. Cancer Res 1992;42:3445-7.
25. Harvey HA, Lipton A, Santen R. Clinical studies with aminoglutethimide in advanced breast carcinoma. Acta Clin Belg 1986;41(11):29-40.
26. Lipton A, Theriault R, Leff R, Gluck S, Stewart J, Costello S, et al. Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate (Aredia) infusions. Proc Am Soc Clin Oncol 1997;531:152a.
27. Bonneterre J, Adenis A, Pion JM, Cambier L, Kamus E, Hecquet B. Aminoglutethimide (AG) and hydrocortisone (HC) in bone metastases: a retrospective study. J Steroid Biochem Mol Biol 1993;44(4-6):693-6.
28. Van Veelen J, Willemse PHB, Tjabbes T, Scweitzer JH, Sleijfer DT. Oral high-dose medroxyprogesterone acetate versus tamoxifen. Cancer 1986;58:7-13.
29. Muss HB, Case LD, Atkins JN, Bearden JD 3rd, Cooper MR, Cruz JM, et al. Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. J Clin Oncol 1994;12:1630-8.
30. Mouridsen HT, Ellemann K, Mattsson W, Palshof T, Daehnfeldt JL, Rose C. Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 1979;63:171-5.
31. Smith IE, Harris AL, Morgan M, et al. Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. BMJ 1981;283:1432-4.
32. Lipton A, Harvey HA, Santen RJ, et al. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer. Cancer Res 1982;42:3434-6.
33. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G, et al. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multi-institutional trials. Cancer 1996;77:2503-13.
34. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel DL, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group, J Clin Oncol 1996;14:2000-11.
35. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205.
36. Conte PF, Latreille J, Maurik L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996;14(9):2522-9.